Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.45 |
| ▸ | OGA | O60502 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 3/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21071424 | 0.90 | MTNR1A (0.47) | MTNR1AOGANQO2MTNR1BSIGMAR1 | |
| SCHEMBL21071682 | 0.89 | CYP19A1 (0.49) | MTNR1ACYP19A1CYP11B1NQO2MTNR1B | |
| SCHEMBL19852304 | 0.88 | MTNR1A (0.49) | MTNR1ANQO2MTNR1BSIGMAR1 | |
| SCHEMBL19852217 | 0.85 | OGA (0.47) | MTNR1AOGACYP19A1CYP11B1KDM4E | |
| SCHEMBL19852179 | 0.83 | MTNR1A (0.48) | MTNR1ANQO2MTNR1BSIGMAR1 | |
| SCHEMBL19852026 | 0.83 | SIGMAR1 (0.49) | MTNR1ANQO2MTNR1BSIGMAR1PDE3B | |
| Hydrochloric Acid SCHEMBL19839321 | 0.82 | MTNR1A (0.47) | MTNR1ANQO2MTNR1BSIGMAR1 | |
| SCHEMBL21071733 | 0.82 | MTNR1A (0.43) | MTNR1ANQO2MTNR1BSIGMAR1 | |
| SCHEMBL19852181 | 0.82 | CCR3 (0.49) | MTNR1ANQO2MTNR1BSIGMAR1 | |
| SCHEMBL19852176 | 0.82 | MTNR1A (0.43) | MTNR1ANQO2MTNR1BSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | MTNR1A 395/4885OGA 3163/4885CYP19A1 2907/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | MTNR1A 395/4885OGA 3163/4885CYP19A1 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.